Claim

Model ledger-default@0.1.0 ledger-strict@0.1.0 ledger-default@0.2.0 ledger-strict@0.2.0 ledger-default@0.3.0 (default) ledger-strict@0.3.0 Snapshot seq

Topics

Medicine · 1efd24fe Public health · 1efd24fe

Assessment

Why?

Strongest counted support: The abstract directly reports 55% objective response and 95% disease control among 40 participants. weight 2.000000 evidence

Suppressed as dependent: The excerpt reports a 55% objective response rate, one complete response, 21 partial responses, and 40 participants.

Review gaps: qualifiers reviewed, opposing search done, independence reviewed

What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Supported.

Show calculation

Your view

Registered views

Checked as part of

Statements this claim was broken out of. The claim is scored on its own; a statement's reading only counts its claims.

• “In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, the...” · 1 claim · 29 September 2026
• “In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, the...” · 1 claim · 29 September 2026
• “In a South Korean phase 1b/2 study of 40 participants with previously untreated HER2-positive advanced biliary tract cancer, a...” · 2 claims · 28 September 2026

Evidence for

• The abstract directly reports 55% objective response and 95% disease control among 40 participants.

  From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-28 Relevance DIRECT Steps 0 Counted

  The abstract directly states the response rate and 40-participant denominator.

• The results passage reports 22 of 40 objective responses and 95.0% disease control.

  From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-28 Relevance DIRECT Steps 0 Counted

  The results directly report 22/40 and 55%.

• Independent ASCO-focused reporting confirms 40 HERBOT participants and a 55% objective response rate for the four-drug regimen.

  From HERBOT at ASCO 2026: Trastuzumab, Nivolumab, Gemcitabine, and Cisplatin in HER2-Positive Biliary Tract Cancer Read 2026-09-29 Relevance STRONG Steps 0 Counted

  This independently presented secondary account corroborates the claim's denominator, regimen context, and response rate; it does not establish superiority to standard care.

• The excerpt reports a 55% objective response rate, one complete response, 21 partial responses, and 40 participants.

  From Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial Read 2026-09-28 Relevance DIRECT Steps 0 Counted

Evidence against

None.

Qualifications

• Independent coverage confirms the 55% response rate as 22 of 40 participants, while noting that this single-arm phase 1b/2 trial had no comparator arm.

  From First-Line Trastuzumab Add-On Reaches 55% Response Rate in HER2-Positive Biliary Tract Cancer Read 2026-09-29 Relevance DIRECT Steps 0 Counted

  Adds useful design context without extending the response-rate result into comparative efficacy.

Suppressed as dependent

Evidence	Group	Kept instead
5167adcb		8be263eb

Inferences

Concluded from

None.

Used as a premise in

None.

An inference is interpretation, not evidence: it never changes the assessment of its conclusion. Each premise is a claim with its own evidence.

Threads

None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.

Claim edges

None. Edges are stored and displayed; v0.1 does not propagate probability across them.

Review checklist

Review checks: 1 of 4

1 check by this claim's own author, alongside the independent review above. 1 EVIDENCE VERIFICATION. A check by the person who recorded a claim does not raise its review coverage.

Check	Done	By
qualifiers reviewed	no
opposing search done	no
independence reviewed	no
primary source reviewed	yes	8be263eb, 85460b32, 1f2b5550

Summary

Contribution history

seq	event	detail
14568	APPENDED
14569	ACCEPT	AUTOMATIC_AFTER_VALIDATION
14580	LINK_EVIDENCE	by 1efd24fe (accepted)
14582	LINK_EVIDENCE	by 1efd24fe (accepted)
15743	LINK_EVIDENCE	by 1efd24fe (accepted)
15901	LINK_EVIDENCE	by 1efd24fe (accepted)
25042	TASK_RESULT	by 1efd24fe (accepted)